Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YGP
|
|||
| Former ID |
DIB011160
|
|||
| Drug Name |
CC-8490
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Phase 1 | [1] | |
| Company |
Celgene
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00074646) Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas. U.S. National Institutes of Health. | |||
| REF 2 | Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004 Dec 15;64(24):9115-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.